Efficacy of interferon-based antiviral therapy in patients with chonic hepatitis C infected HCV genotype 5: a meta-analysis of two large prospective clinical trials
D'Heygere, F.; George, C.; Van Vlierberghe, H.et al.
2011 • In Journal of Medical Virology, 83 (5), p. 815-819
[en] The characteristics and response rate to pegylated interferon and ribavirin (PEG-INF + RBV) of patients with chronic hepatitis C infected with genotype 5 are poorly documented. A meta-analysis of two large phase III/IV prospective randomized clinical trials conducted in Belgium in patients with chronic hepatitis C (n = 1,073 patients) was performed in order to compare the response to antiviral therapy of hepatitis C virus (HCV) genotype 5 with that of other HCV genotypes. A subset of HCV-1 infected patients selected from within the study database were selected to match the HCV-5 sample for known prognostic factors. In Belgium HCV-5 is responsible for a significant minority of cases of chronic hepatitis C CHC (4.5%) and is characterized by a more advanced age (58.4 years), a high frequency of cirrhosis (27.7%), a specific mode of HCV acquisition, and a particular geographic origin (66.7% of patients from West Flanders). The primary comparative analysis showed that response to treatment with PEG-INF + RBV of HCV-5 is similar to HCV-1 and lower compared to HCV-2/3. The analysis of the matched patient subgroup demonstrates that the HCV-5 "intrinsic sensitivity" to PEG-IFN + RBV therapy is identical to HCV-1, with a sustained virological response of 55% in both groups. In contrast to previous publications, this meta-analysis suggests that HCV-5 response to treatment is closer to HCV-1 than to HCV-2/3 and suggests that in Belgium HCV-5 infection should be treated with the same antiviral regimen as HCV-1.
Disciplines :
Gastroenterology & hepatology
Author, co-author :
D'Heygere, F.
George, C.
Van Vlierberghe, H.
Decaestecker, J.
Nakad, A.
Adler, M.
Delwaide, Jean ; Université de Liège - ULiège > Gastro-Entérologie-Hépatologie
Laureys, A.
Nevens, F.
Language :
English
Title :
Efficacy of interferon-based antiviral therapy in patients with chonic hepatitis C infected HCV genotype 5: a meta-analysis of two large prospective clinical trials
Publication date :
May 2011
Journal title :
Journal of Medical Virology
ISSN :
0146-6615
eISSN :
1096-9071
Publisher :
Wiley Liss, Inc., New York, United States - New York
Antaki N, Hermes A, Hadad M, Ftayeh M, Antaki F, Abdo N, Kebbewar K. 2008. Efficacy of interferon plus ribavirin in the treatment of hepatitits C virus genotype 5. J Viral Hepat 15: 383-386.
Beutels M, Van Damme P, Aelvoet W, Desmyter J, Dondeyne F, Goilav C, Mak R, Muylle L, Pierard D, Stroobant A, Van Loock F, Waumans P, Vranckx R. 1997. Prevalence of hepatitis A, B and C in the Flemish population. Eur J Epidemiol 13: 275-280.
Blatt LM, Mutchnick MG, Tong MJ, Klion FM, Lebovics E, Freilich B, Bach N, Smith C, Herrera J, Tobias H, Conrad A, Schmid P, McHutchison JG. 2000. Assessment of hepatitis C virus RNA and genotype from 6807 patients with chronic hepatitis C in the United States. J Viral Hepatol 7: 196-202.
Bonny C, Fontaine H, Poynard T, Hézode C, Larrey D, Marcellin P, Bourlière M, Bronowicki JP, Merle P, Zarski JP, Sapey T, Guillemard C, Ughetto S, Henquell C, Nicolas C, Roche C, Randl K, Bommelaer G, Abergel A. 2006. Effectiveness of interferon plus ribavirin combination in the treatment of naïve patients with hepatitis C virus type 5. A French multicentre retrospective study. Aliment Pharmacol Ther 24: 593-600.
Chamberlain RW, Adams NJ, Taylor LA, Simmonds P, Elliott RM. 1997. The complete coding sequence of hepatitis C virus genotype 5a, the predominant genotype in South Africa. Biochem Biophys Res Commun 236: 44-49.
Deltenre P, Henrion J, Canva V, Dharancy S, Texier F, Louvet A, De Maeght S, Paris JC, Mathurin P. 2004. Evaluation of amantadine in chronic hepatitis C: A meta-analysis. J Hepatol 41: 462-473.
Delwaide J, Gerard C, Reenaers C, Vaira D, Bastens B, Bataille C, Servais B, Maes B, Belaiche J, Hepatotropes GL, Groupe Liegeois D'etudes Des Virus Hepatotropes (GLEVE). 2005. Hepatitis C virus genotype 5 in southern Belgium: Epidemiological characteristics and respons to therapy. Dig Dis Sci 50: 2348-2351.
Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Goncales FL, Jr., Haussinger D, Diago M, Carrosi G, Dhumaux D, Craxi A, Lin A, Hoffman J, Yu J. 2002. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 347: 975-982.
Gerard C, Delwaide J, Vaira D, Bastens B, Servais B, Wain E, Bataille C, Daenen G, Belaïche J. 2005. Evolution over a 10 year period of the epidemiological profile of 1726 newly diagnosed HCV patients in Belgium. J Med Virol 76: 503-510.
Henquell C, Carteau C, Abergel A, Laurichesse H, Regagnon C, De Champs C, Bailly JL, Peigue-Lafeuille H. 2004. High prevalence of hepatitis C virus Type 5 in Central France evidenced by a prospective study from 1996 to 2002. Clin J Microbial 42: 3030-3035.
Jover R, Pérez-Serra J, de Vera F, Alamo JM, Muñoz C, Yago C, Martínez-Ramírez R, Vidal JV. 2001. Infection by genotype 5a of HCV in a district of southeast Spain. Am J Gastroenterol 96: 3042-3043.
Kleter B, Brouwer JT, Nevens F, van Doorn LJ, Elewaut A, Versieck J, Michielsen PP, Hautekeete ML, Chamuleau RA, Brénard R, Bourgeois N, Adler M, Quint WG, Bronkhorst CM, Heijtink RA, Hop WJ, Fevery J, Schalm SW. 1998. Hepatitis C virus genotypes: Epidemiological and clinical associations. The Benelux Study Group on treatments of chronic hepatitis C. Liver 18: 32-38.
Langlet P, D'Heygere F, Henrion J, Adler M, Delwaide J, Van Vlierberghe H, Mulkay JP, Lasser L, Brenard R, Horsmans Y, Michielsen P, Laureys A, Nevens F. 2009. A randomized trial of pegylated-interferon-α-2a plus ribavirin with or without amantadine in treatment-naïve or relapsing chronic hepatitis C patients. Aliment Pharmacol Ther 30: 352-363.
Legrand-Abravanel F, Sandres-Sauné K, Barange K, Alric L, Moreau J, Desmorat P, Vinel JP, Izopet J. 2004. Hepatitis C virus genotype 5: Epidemiological characteristics and sensitivity to combination therapy with interferon-α plus ribaverin. J Infect Dis 189: 1397-1400.
Nevens F, Van Vlierberghe H, D'Heygere F, Delwaide J, Adler M, Henrion J, Lenaerts A, Hendlisz A, Michielsen P, Bastens B, Brenard R, Laureys A, the BERNAR-1 Study Group. 2010. A randomized, open-label, multicenter study evaluation the efficacy of peginterferon alfa-2a versus interferon alfa-2a, in combination with ribavirin, in naïve and relapsed chronic hepatitis C patients. Acta Gastroenterol Belg 73: 223-228.
Ross RS, Viazov S, Renzing-Köhler K, Roggendorf M. 2000. Changes in the epidemiology of hepatitis C infection in Germany: Shift in the predominance of hepatitis C subtypes. J Med Virol 60: 122-125.
Simmonds P. 1995. Variability of hepatitis C virus. Hepatology 21: 570-581.
Verbeeck J, Maes P, Wollants E, Van der Merwe S, Song E, Nevens F, Van Ranst M. 2005. Use of a commercially available line probe assay for genotyping of hepatitis C virus 5a strains. J Clin Microbiol 43: 6117-6119.
Verbeeck J, Maes P, Lemey P, Pybus OG, Wollants E, Song E, Nevens F, Fevery J, Delport W, Van der Merwe S, Van Ranst M. 2006. Investigating the origin and spread of Hepatitis C virus genotype 5a. J Virol 80: 4220-4226.
Verbeeck J, Peigne-Lafeuille H, Ross S, Abergel A, Nevens F, Van der Merwe S, Van Ranst M. 2007. HCV genotype 5: Epidemiology and spread of an uncommon genotype. J Clin Virol 41: 170-171.
